Thromb Haemost 1987; 58(01): 564
DOI: 10.1055/s-0038-1644894
Abstracts
SUPPLEMENTARY ABSTRACTS
Schattauer GmbH Stuttgart

EFFECTS OF INTRAVENOUS ADMINISTRATIONOF A TISSUE-TYPE PLASMINOGEN ACTIVATOR (AK-124) IN ACUTE MYOCARDIAL INFARCTION, INCLUDING CHANGES IN BLOOD COAGULATION AND FIBRINOLYTIC ACTIVITY.- PRELIMINARY REPORT

T Honda
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
M Aosaki
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
T Tanaka
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
M Aosaki
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
T Uchida
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
S Kimata
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
K Hirosawa
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
Y Horikawa
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
S Ishizuka
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
,
K Ohki
The Heart Institute of Japan, Tokyo Wome's Medical College, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
23 August 2018 (online)

We administered a tissue-type plasminogen activator (t-PA) intravenously to 10 patients with acute myocardial infarction (AMI), within 6 hours after the onset of symptoms, and then examined the state of reperfusion by coronary arterio graphy (CAG), and observed changes in blood coagulation and fibrinolytic activity to evaluate the drug effects. AK-124 (produced by Asahi Chemical Industry and Kowa Co., Ltd.in collaboration), a t-PA produced the by tissue cultureof normal human lung cells, was given in a dosage of48,000_576,000 A.K. units by intravenous infusionover 30_45 minutes. In 7 patients who received t-PA, areflow or improved flow was detected on CAG. In t-PAtreated patients, euglobulin lysis activity clearly increased, euglobulin lysis time clearly shortened, and D-dimer increased. After t-PA treatment, the levels of circulating fibrinogen and a2-plasmin inhibitor decreased by an average of 12%, and 14% of base-line values respectively, but plasminogen showed no detectable change. A hematoma at the site of the catheter insertion was observed in one patient. These observations suggest that t-PA has a higher specificity for fibrin bound plasminogen than for plasma plasminogen, and produces coronary thrombolysis without causing systemic fibrinolysis, at least with the above dosage.